These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35547260)
1. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma. Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y Front Genet; 2022; 13():886983. PubMed ID: 35547260 [No Abstract] [Full Text] [Related]
2. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Huang X; Zhang G; Tang T; Liang T Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511 [TBL] [Abstract][Full Text] [Related]
3. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584 [TBL] [Abstract][Full Text] [Related]
4. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Huang X; Tang T; Zhang G; Liang T Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460 [TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma. Wei S; Sun Q; Chen J; Li X; Hu Z Front Genet; 2022; 13():1068112. PubMed ID: 36579327 [No Abstract] [Full Text] [Related]
6. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development. Wang F Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600 [TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D Front Immunol; 2022; 13():773264. PubMed ID: 35185876 [TBL] [Abstract][Full Text] [Related]
8. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development. Ma S; Ba Y; Ji H; Wang F; Du J; Hu S Front Immunol; 2021; 12():738435. PubMed ID: 34603319 [TBL] [Abstract][Full Text] [Related]
9. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development. Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794 [TBL] [Abstract][Full Text] [Related]
10. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine. Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ Front Immunol; 2021; 12():709986. PubMed ID: 34512630 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination. You W; Ouyang J; Cai Z; Chen Y; Wu X Front Immunol; 2022; 13():827506. PubMed ID: 35874675 [TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma. Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349 [TBL] [Abstract][Full Text] [Related]
13. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q J Big Data; 2022; 9(1):92. PubMed ID: 35855914 [TBL] [Abstract][Full Text] [Related]
14. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development. Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D Front Genet; 2021; 12():701065. PubMed ID: 34527020 [No Abstract] [Full Text] [Related]
15. Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma. Lin Q; Liang L; Wang Q; Wang X; You Y; Rong Y; Zhou Y; Guo X Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672082 [TBL] [Abstract][Full Text] [Related]
16. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications. Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342 [TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development. Wang G; Gao Y; Chen Y; Wang K; Zhang S; Li G Front Oncol; 2022; 12():921711. PubMed ID: 35814377 [TBL] [Abstract][Full Text] [Related]
18. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. Lu TL; Li CL; Gong YQ; Hou FT; Chen CW World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406 [TBL] [Abstract][Full Text] [Related]
19. Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection. Zhu D; Yang J; Zhang M; Han Z; Shao M; Fan Q; Ma Y; Xie D; Xiao W Aging (Albany NY); 2023 Jun; 15(11):5190-5214. PubMed ID: 37315301 [TBL] [Abstract][Full Text] [Related]
20. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients. Fei H; Chen X Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]